Deepcell Scores $73 Million Series B

<p><strong>MENLO PARK<&sol;strong> &&num;8212&semi; Deepcell&comma; a life science company pioneering AI-powered single cell classification and isolation for basic and translational research&comma; has closed &dollar;73 million Series B round of financing&period; The new funding will allow Deepcell to continue product development and enable early commercial introduction of a new standard for obtaining biological insights from single cell analysis&period; Deepcell’s platform combines advances in AI&comma; proprietary microfluidics&comma; high resolution optics&comma; and a growing cell atlas with over 1 billion images to analyze and sort cells based on visual features&period; This allows researchers to characterize and gain new insights from single cells at levels of resolution previously unseen with other &OpenCurlyDoubleQuote;omics” based tools&period;<&sol;p>&NewLine;<p>This new round of funding was led by Koch Disruptive Technologies and joined by new investors including Bridger Healthcare&comma; Horizons Ventures&comma; Casdin Capital and lead investors from previous rounds&comma; Andreessen Horowitz and Bow Capital as well as Jeff Dean&comma; Head of Google Brain&comma; and Matt Mcllwain&comma; Managing Director at Madrona Venture Group&period; This Series B financing brings Deepcell’s overall funding to nearly &dollar;100 million since the company was founded in 2017&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The new funding will help us to accelerate our growth&comma; develop our platform&comma; and take a major step toward full commercialization&comma;” said Maddison Masaeli&comma; CEO and Co-founder of Deepcell&period; &OpenCurlyDoubleQuote;The support we are receiving highlights the potential of Deepcell’s AI-powered single cell morphology analysis&comma; and enables us to expand the team&comma; transition to late-stage development and accelerate towards introducing our platform to a present and growing list of potential customers&period;”<&sol;p>&NewLine;<p>Unlike other cell analysis approaches&comma; Deepcell’s technology was developed to isolate and collect label-free single cells based on morphology&comma; keeping the cell intact&comma; which is critical for downstream biological characterization&period; By analyzing whole&comma; unperturbed single cell populations instead of molecular targets on or within cells&comma; Deepcell’s technology gives researchers access to a brand new dimension in cell biology and the ability to understand cellular heterogeneity in rich detail&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Deepcell is advancing the use of computational methods with our deep learning capabilities to help fulfill the promise of precision medicine&comma;” said Mahyar Salek&comma; President&comma; CTO and Co-founder of Deepcell&period; &OpenCurlyDoubleQuote;AI can learn to identify cells based on visual differences that are hardly accessible to the human eye and can continually improve&comma; thanks to our capability to sort cells and thereby elicit ground truth at scale&period; With training on billions of cell images and sorting cells&comma; our AI technology connects morphology to multiomics&comma; delivering unprecedented access to the exciting world of biology&period;”<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are thrilled to support Deepcell’s vision as the market leader in single cell morpholomics&comma;” said David Mauney&comma; Managing Director at KDT and new Board member at Deepcell&period; &OpenCurlyDoubleQuote;The company has clearly demonstrated the ability to provide unique biological insights previously unattained by existing approaches&period; We look forward to working with the team to expand their product offering and prepare for full commercialization&period;”<&sol;p>&NewLine;